Alkermes Appoints Joshua Reed as Chief Financial Officer

Core Insights - Alkermes plc has appointed Joshua Reed as Chief Financial Officer (CFO), effective September 15, 2025, reporting to CEO Richard Pops [1] - Mr. Reed has over 30 years of financial leadership experience, particularly in the biotechnology and pharmaceutical sectors, previously serving as CFO at Omega Therapeutics and Aldeyra Therapeutics [2] - The CEO expressed confidence in Mr. Reed's financial expertise and strategic insight, highlighting the importance of his role in driving performance and shareholder value [4] Company Overview - Alkermes plc is a global biopharmaceutical company focused on developing innovative medicines in neuroscience, with a portfolio addressing alcohol dependence, opioid dependence, schizophrenia, and bipolar I disorder [4] - The company has a pipeline of clinical and preclinical candidates for neurological disorders, including narcolepsy and idiopathic hypersomnia [4] - Alkermes is headquartered in Ireland, with additional offices in Massachusetts and a manufacturing facility in Ohio [4]